CUDC 101

Drug Profile

CUDC 101

Alternative Names: CUDC-101

Latest Information Update: 06 Oct 2015

Price : $50

At a glance

  • Originator Curis
  • Class Antineoplastics; Hydroxamic acids; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 01 Jun 2014 Curis terminates a phase I clinical trials in Solid tumours (late-stage disease) in USA (NCT01702285)
  • 30 Nov 2012 Curis terminates a planned phase I trial in Breast cancer in the United Kingdom (EudraCT 2012-003064-47)
  • 01 Sep 2012 Phase-I clinical trials in Solid tumours (late-stage disease) in USA (PO) (NCT01702285)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top